【摘要】 目的探讨局部区域晚期鼻咽癌实施同期放化疗联合尼妥珠单抗靶向治疗的效果。方法 50例表皮生长因子受体(EGFR)过表达局部区域晚期鼻咽癌患者,采用计算机随机分为联合组和同期放化疗组,每组25例。联合组患者采用同期放化疗联合尼妥珠单抗靶向治疗,同期放化疗组患者采用同期放化疗治疗。比较两组患者近期疗效、治疗前后肿瘤学指标、毒副反应发生情况。结果联合组患者肿瘤局部控制率为92.0%,高于同期放化疗组的68.0%,差异具有统计学意义(P<0.05)。治疗后3个月,两组患者血浆EB病毒脱氧核糖核酸(EBV-DNA)水平均低于本组治疗前,且联合组(2014.5±417.2)copies/ml低于同期放化疗组的(3148.5±587.3)copies/ml,差异具有统计学意义(P<0.05)。两组患者治疗期间消化道反应、骨髓抑制、放射性损伤、肝肾功能损伤发生率比较差异无统计学意义(P>0.05)。结论局部区域晚期鼻咽癌(EGFR过表达者)实施同期放化疗联合尼妥珠单抗靶向治疗可提高近期疗效,提高肿瘤局部控制率,且不增加毒副反应。更多还原

【Abstract】 Objective To discuss the effect of concurrent radiochemotherapy combined with nimotuzumab targeted therapy for locally advanced nasopharyngeal carcinoma. Methods A total of 50 cases of locally advanced nasopharyngeal carcinoma with overexpression of epidermal growth factor receptor(EGFR) were divided into combination group and concurrent radiochemotherapy group by computer random method, with 25 cases in each group. Combination group was treated by concurrent radiochemotherapy, and concurrent radiochemotherapy group was treated by concurrent radiochemotherapy. The short-term efficacy, oncology index before and after treatment and occurrence of toxic side effects was compared in the two groups.Results The local control rate of tumor was 92.0% in combination group, which was higher than 68.0% in concurrent radiochemotherapy group, and the difference was statistically significant(P<0.05). After 3 months of treatment, the levels of plasma EB deoxyribonucleic acid(EBV-DNA) in the two groups was lower than those before treatment, and the combination group(2014.5±417.2) copies/ml was lower than(3148.5±587.3) copies/ml in concurrent radiochemotherapy group. Their difference was statistically significant(P<0.05). There was no statistically significant difference in incidence of gastrointestinal reaction, myelosuppression, radiation injury, liver and kidney function injury during the treatment between the two groups(P>0.05). Conclusion For locally advanced nasopharyngeal carcinoma(EGFR overexpressor), concurrent chemoradiotherapy combined with nimotuzumab targeted therapy can improve short-term efficacy, improve local control rate of tumor without increasing toxic side effects.更多还原